Why John Paulson Can't Rescue Valeant's Stock

This is source I found from another site, main source you can find in last paragraph

What's more, Bloomberg data, which estimated Paulson's average cost basis based on 13F filings with the Securities and Exchange Commission, suggests that Paulson is losing money on eight out of his nine largest healthcare holdings. This includes nearly a 90% decline in the price of Valeant, a nearly 80% implosion by 

Endo International, and a veritable halving in price from branded and generic drugmaker

Teva Pharmaceutical Industries. Again, this data is estimated, but it pretty clearly demonstrates that Paulson's healthcare intuition hasn't been the greatest over the past couple of years. The old adage, "Past performance is no guarantee of future results," is on display here.

This is source I found from another site, main source you can find in last paragraph

Source : http://www.pantagraph.com/business/investment/markets-and-stocks/john-paulson-joining-valeant-pharmaceuticals-board-isn-t-a-sufficient/article_1277a3ab-7ded-5859-b85b-d1f38a71e138.html

business

various

John Paulson Joining Valeant Pharmaceuticals' Board Isn't a Sufficient Reason to Get Excited
Why the Fall of Valeant Pharmaceuticals’ CEO Is Good for You
Why Valeant Pharmaceuticals Intl Inc. Dropping Is of Little Consequence
Phony Obamacare Attack Aimed at Luring Conservatives to Support a Hedge Fund Windfall
Bill Ackman's Big Pharma Trade Is Making Wall Street A Very Awkward Place
Ackman Hints At Herbalife’s Enron-Like Fraud [TRANSCRIPT]
Tracking the Storm
7 of the Nastiest Scams, Rip-Offs and Tricks From Wall Street Crooks